NCT03047083View on ClinicalTrials.gov

Treatment Patterns and Key Healthcare Resource Use in Acute Myeloid Leukemia (AML) With or Without FMS-like Tyrosine Kinase-3 (FLT3) Mutation Study Based on Retrospective Chart Review

CompletedOBSERVATIONAL
Enrollment

1,027

Participants

Timeline

Start Date

June 2, 2014

Primary Completion Date

March 18, 2016

Study Completion Date

March 18, 2016

Conditions
Acute Myeloid Leukemia (AML)
Interventions
OTHER

Treatment patterns among AML patients

This is a retrospective cohort study of AML patients with or without FLT3 mutation who were exposed to treatments for AML per treating physician's decision between 1 January 2013 and 31 December 2015.

OTHER

AML-related healthcare resources

This is a retrospective cohort study of AML patients with or without FLT3 mutation who were exposed to treatments for AML per treating physician's decision between 1 January 2013 and 31 December 2015.

Trial Locations (1)

28209

Sermo, Charlotte

All Listed Sponsors
lead

Astellas Pharma Global Development, Inc.

INDUSTRY

NCT03047083 - Treatment Patterns and Key Healthcare Resource Use in Acute Myeloid Leukemia (AML) With or Without FMS-like Tyrosine Kinase-3 (FLT3) Mutation Study Based on Retrospective Chart Review | Biotech Hunter | Biotech Hunter